News about Clinical Trials

Axsome Doses First Patient in Phase 3 Trial of Solriamfetol for Adolescent ADHD

Axsome Therapeutics has initiated patient dosing in the Phase 3 FOCUS-3 trial evaluating solriamfetol as a potential treatment for adolescents with Attention Deficit Hyperactivity Disorder.

Clinical Trials | 01/07/2026 | By News Bureau

AbbVie Reports Positive Phase 3 Results for Epcoritamab in Diffuse Large B-Cell Lymphoma

AbbVie reported positive phase 3 results for epcoritamab plus lenalidomide, showing improved Progression-Free Survival (PFS) in patients with relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL).

Clinical Trials | 01/07/2026 | By News Bureau

Viatris Reports Positive Phase 3 Results for VR-205 in IgA Nephropathy in Japan

Viatris reported positive Phase 3 results for VR-205 in Japanese adults with primary IgA nephropathy and plans to submit a New Drug Application (NDA) in Japan by the end of 2026.

Clinical Trials | 01/07/2026 | By News Bureau

Sanofi's Nexviazyme Meets Primary Goal in Phase 3 Study for Infantile-Onset Pompe Disease

Sanofi's Phase 3 Baby-COMET study showed Nexviazyme improved ventilator-free survival in infants with infantile-onset Pompe disease, supporting plans for a US regulatory filing to expand the therapy's approved indication.

Clinical Trials | 01/07/2026 | By News Bureau

Alexion Reports Positive Phase 3 Results for Efzimfotase Alfa in Children with Rare Bone Disease

Alexion, AstraZeneca Rare Disease, has announced positive Phase 3 results for investigational enzyme replacement therapy efzimfotase alfa in children with HPP. The therapy demonstrated significant improvements in bone health and physical function, reinforcing its potential as a next-generation treatment for the rare inherited metabolic disorder.

Clinical Trials | 30/06/2026 | By News Bureau

NeuroSense Reports Positive Phase 2 Biomarker Results for PrimeC in Alzheimer's Disease Trial

PrimeC shows encouraging biomarker activity in Phase 2 Alzheimer’s study, supporting its potential as a multi-target therapy for neurodegenerative diseases.

Clinical Trials | 26/06/2026 | By News Bureau |  145

Racura Oncology Doses First Patient in Phase 1 Trial of RC220 Combination Therapy for EGFR-Mutant Lung Cancer

HARNESS-1 study evaluates RC220 with osimertinib to address treatment resistance in EGFR-mutant non-small cell lung cancer, with the first patient showing no adverse events after initial dosing.

Clinical Trials | 26/06/2026 | By News Bureau

Boehringer Ingelheim Launches 3 Phase 3 Trials to Advance Precision Oncology in Hard-to-Treat Cancers

Boehringer Ingelheim has initiated 3 phase 3 oncology trials, including DAREON-Lung-1 and DAREON-NEC-1, to evaluate obrixtamig as a DLL3 biomarker-guided treatment approach for hard-to-treat cancers.

Clinical Trials | 23/06/2026 | By News Bureau

CureGene Doses First Patient in Pivotal US Trial of Evategrel

CureGene achieves first participant dosed in US pivotal trial for Evategrel (CG-0255), a best-in-class antiplatelet drug, accelerating global commercialisation.

Clinical Trials | 23/06/2026 | By News Bureau |  172

Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 3 ATLAS-UC Induction

Merck’s tulisokibart achieved both primary and key secondary endpoints in the phase 3 ATLAS-UC induction study, demonstrating significant efficacy in patients with moderately to severely active Ulcerative Colitis (UC).

Clinical Trials | 23/06/2026 | By News Bureau |  285